Previous Close | 18.67 |
Open | 18.79 |
Bid | 19.06 x 1000 |
Ask | 19.07 x 800 |
Day's Range | 18.30 - 19.09 |
52 Week Range | 10.60 - 28.62 |
Volume | |
Avg. Volume | 781,504 |
Market Cap | 3.048B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.63 |
CERT vs. PBYI: Which Stock Is the Better Value Option?
Certara improves software capabilities by expanding into deep learning and data fabricPRINCETON, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art ar
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private EquityPRINCETON, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara. David Spaight, an Operating Partner at Arsenal, has been appointed to Certara’s Bo